6 completed, 1 terminated. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 3 | Completed 3 |
Follow GLPG2222: new trials by email Literature Review of GLPG2222 trials Research Report on GLPG2222
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor Galicaftor, Navocaftor - Healthy Volunteers | Phase 1 | Completed | AbbVie | 24 | 2022-09-27 | 2023-01-17 |
| Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis ABBV-576, Galicaftor, Placebo - Cystic Fibrosis (CF) | Phase 2 | Terminated | AbbVie | 48 | 2021-09-20 | 2024-07-16 |
| A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 ABBV-3067, Placebo ABBV-3067, ABBV-2222 - Cystic Fibrosis | Phase 2 | Completed | AbbVie | 78 | 2019-12-11 | 2023-06-28 |
| A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. GLPG2451 dose regimen A, GLPG2451 dose regimen B, GLPG2222 - Cystic Fibrosis | Phase 1 | Completed | Lakefront Biotherapeutics NV | 10 | 2018-05-31 | 2019-04-08 |
| A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis GLPG2222 50 mg, GLPG2222 100 mg, Placebo - Cystic Fibrosis | Phase 2 | Completed | Lakefront Biotherapeutics NV | 59 | 2017-03-18 | 2018-11-16 |
| A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis GLPG2222 150 mg q.d., GLPG2222 300 mg q.d., Placebo - Cystic Fibrosis | Phase 2 | Completed | Lakefront Biotherapeutics NV | 37 | 2017-01-01 | 2017-11-21 |
| First-in-Human Single and Multiple Dose of GLPG2222 GLPG2222 single dose, Placebo single dose, GLPG2222 multiple doses - Healthy | Phase 1 | Completed | Lakefront Biotherapeutics NV | 40 | 2016-01-01 | 2016-07-29 |
Cystic Fibrosis (5)
Lakefront Biotherapeutics NV (4) · AbbVie (3)
Belgium (6) · Netherlands (4) · United Kingdom (4) · United States (4) · Serbia (3) · Australia (2) · Czechia (2) · Germany (2) · Hungary (2) · New Zealand (2) · Slovakia (2) · Bulgaria (1) · Canada (1) · France (1) · Greece (1)
Olivier Van Steen, MD, MBA (2) · Kirsteen Donaldson, MD (1) · Olivier Van de Steen, MD MBA (1)
PMID 31056441, PMID 33331662, PMID 37983082
2015 (1), 2017 (1), 2019 (1)